Vistagen Therapeutics Corporate Presentation

Vistagen Therapeutics presented a corporate overview on March 16, 2026, highlighting its pioneering work in neuroscience through nose-to-brain neurocircuitry. The company focuses on developing a novel class of rapid-onset intranasal product candidates called Pherines, which are chemically distinct synthetic steroid-like structures. These Pherines are designed to directly modulate neurocircuits involved in physiological and emotional behaviors without systemic absorption or direct action on brain neurons. The presentation detailed Vistagen's diverse pipeline, including five clinical-stage product candidates targeting neuropsychiatry, women's health, and cancer supportive care. Key candidates discussed include Fasedienol for acute social anxiety disorder, Itruvone for major depressive disorder, Refisolone for menopausal vasomotor symptoms and PMDD, PH15 for cognitive impairment due to mental fatigue, and PH284 for cancer cachexia. The company emphasized the significant unmet needs in these therapeutic areas and the potential of its Pherine platform to offer differentiated, non-systemic treatments.